Proximity extension assay-based proteomics studies in neurodegenerative disorders and multiple sclerosis
Burak I Arioz1,2, Aysen Cotuk1,2, Emiş Cansu Yaka3
1Izmir Biomedicine and Genome Center, Izmir, Turkey.
The European Journal of Neuroscience
|December 18, 2023
Summary
Discovering new blood-based biomarkers is crucial for early diagnosis of neurodegenerative diseases. Proximity extension assay offers a sensitive method for identifying these vital protein biomarkers.
Area of Science:
- Neuroscience
- Proteomics
- Biomarker Discovery
Background:
- Neurodegenerative diseases cause progressive nervous system damage, often with overlapping symptoms, complicating early diagnosis.
- Current diagnostic methods struggle with early detection as pathological changes precede clinical signs.
- There is a continuous need for more accurate and abundant biomarkers, especially blood-based ones, for timely intervention.
Purpose of the Study:
- To review the application of proximity extension assay (PEA) technology in identifying protein biomarkers for neurodegenerative diseases.
- To highlight the potential of PEA in advancing early and accurate diagnosis of these conditions.
Main Methods:
- Proximity extension assay (PEA) is a proteomics technique utilizing antibody-oliogonucleotide conjugates for protein quantification via real-time PCR.
- PEA enables sensitive detection of low-abundance proteins from small sample volumes, outperforming conventional methods.
Main Results:
- The review explores the use of PEA for detecting protein biomarkers and profiles associated with various neurodegenerative diseases.
- PEA demonstrates high sensitivity and efficiency in identifying potential diagnostic markers.
Conclusions:
- Proximity extension assay is a promising technology for discovering blood-based biomarkers for neurodegenerative diseases.
- This approach facilitates earlier and more precise diagnosis, potentially improving patient outcomes.
